A routine prostate exam usually involves two quick components: a blood draw to measure prostate-specific antigen (PSA) and a digital rectal exam (DRE) in which a clinician feels the prostate through the rectal wall with a gloved, lubricated finger. The whole thing is over in minutes, and neither part requires any special preparation from you. But those few minutes sit at the front of a screening pathway that can branch into blood-based biomarker tests, MRI scans, and biopsies, so understanding what each step involves and what comes next helps take some of the mystery out of the process.
The PSA Blood Test
The first part of a prostate exam looks like any other blood draw. A technician takes a small sample from your arm, and the lab measures PSA, a protein produced almost exclusively by the prostate gland. PSA’s actual job is to break down proteins in semen after ejaculation; only small amounts normally leak into the bloodstream.1PubMed. Biology of prostate-specific antigen When PSA levels in the blood are higher than expected, it can signal that something is happening in the prostate, but “something” does not automatically mean cancer. Benign prostate enlargement, prostate inflammation, urinary retention, recent catheterization, and even normal aging can all push PSA numbers up.2PubMed Central. Lifestyle and risk factors associated with elevated prostate-specific antigen levels in rural men: implications for health counseling
You do not need to fast for the blood draw, though your doctor may ask you to avoid ejaculation for a day or two before the test, since that can temporarily elevate PSA. Results typically come back within a few days. A PSA level under about 4 ng/mL is generally considered normal, but that cutoff is a rough guide, not a bright line. Some men with PSA below 4 have cancer, and many men with PSA above 4 do not. The number is most useful as one data point alongside other information.
The Digital Rectal Exam
The DRE is the part of the exam that generates the most anxiety, so knowing exactly what happens can help. You will be asked to either bend forward over the exam table, lie on your side with your knees drawn up, or stand and lean on the table. The clinician puts on a glove, applies lubricant to one finger, and gently inserts it into the rectum. Because the prostate sits just in front of the rectal wall, the clinician can feel its surface through the tissue. They are checking for lumps, hard spots, asymmetry, or unusual size. The whole thing takes about ten to fifteen seconds.
It feels like pressure. Most men describe it as uncomfortable but not painful. A study that measured discomfort on a visual scale found average pain scores around 37 out of 100, roughly comparable to getting blood drawn in a tricky vein.3PubMed. Male discomfort during the digital rectal examination: does examiner gender make a difference? The same study found that younger men tended to report both more pain and more embarrassment than older men, while the gender of the examiner did not make a meaningful difference in either category. Lack of information about what to expect is one of the biggest contributors to a negative experience, so simply reading about the process ahead of time tends to help.4PubMed Central. Digital Rectal Exam in the Acute Hospital Setting: Bridging Patient Experience and the Physician Perspective
A DRE is not a perfect test. It can only evaluate the back surface of the prostate, so cancers on the far side or deep within the gland may be missed entirely. It is also subjective: what one clinician interprets as a suspicious nodule, another might not. That is why PSA and DRE are almost always used together rather than in isolation.
How Well Do These Tests Detect Cancer?
Neither PSA nor DRE on its own is a highly reliable cancer detector, but combining them improves the odds. In a multicenter trial of more than 6,600 men, PSA picked up about 82% of the cancers that were eventually confirmed, compared with 55% for the DRE. When both methods were used together, the detection rate climbed to nearly 6%.5The Journal of Urology. Comparison of Digital Rectal Examination and Serum Prostate Specific Antigen in the Early Detection of Prostate Cancer: Results of a Multicenter Clinical Trial of 6,630 Men A more recent systematic review and meta-analysis confirmed that PSA has higher sensitivity and specificity than DRE across multiple ethnic populations.6African Journal of Urology. Clinical diagnosis of prostate cancer using digital rectal examination and prostate-specific antigen tests: a systematic review and meta-analysis of sensitivity and specificity
One thing to note: the positive predictive value of PSA alone in that large trial was about 32%, meaning that out of every three men with elevated PSA who went on to further testing, roughly two did not turn out to have cancer. That is not a flaw so much as a feature of what PSA is: a sensitive but nonspecific flag. It catches a lot of true cancers at the cost of also flagging plenty of men who do not have one. The rest of the screening pathway exists to sort the two groups apart.
When Should You Get Screened?
The major medical organizations agree on the broad strokes but differ in the fine print. Both the U.S. Preventive Services Task Force (USPSTF) and the American Urological Association (AUA) recommend that men aged 55 to 69 have a conversation with their doctor about whether PSA-based screening is right for them, a practice called shared decision-making.7PubMed Central. Early detection of prostate cancer: AUA Guideline The USPSTF recommends against routine PSA screening for men 70 and older, because the potential harms of follow-up treatment often outweigh the benefits at that age.8Journal of the American Medical Association. Screening for Prostate Cancer Updated AUA guidelines also encourage tailored screening intervals based on individual risk rather than a one-size-fits-all annual test.9PubMed Central. Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening
The “talk with your doctor” recommendation frustrates some men who just want a clear yes-or-no answer. The reason it exists is that PSA screening catches cancers early, but some of those cancers grow so slowly they would never cause symptoms or shorten a life. Screening can lead to biopsies and treatments that carry real side effects, including urinary incontinence and erectile dysfunction. Whether those risks are worth the benefit of early detection depends on your age, health, family history, and personal values, which is why guidelines frame it as a decision rather than a mandate.
Earlier Screening for Higher-Risk Groups
Not everyone follows the same timeline. The National Comprehensive Cancer Network (NCCN) and the AUA recommend that men at increased risk begin screening with both PSA and DRE at age 40.10PubMed Central. Screening guidelines for individuals at increased risk for prostate cancer “Increased risk” includes men with a strong family history of prostate cancer, men who carry certain inherited gene mutations, and Black men, who develop prostate cancer at higher rates and at younger ages than men of other backgrounds.
The data behind earlier screening for Black men is especially clear. Modeling studies suggest prostate cancer develops three to nine years earlier in Black men compared with non-Black men. The Prostate Cancer Foundation’s guidelines recommend that baseline PSA conversations start in the early 40s, and that lowering the screening starting age to 40 to 45, followed by regular testing through age 70, could reduce prostate cancer deaths in Black men by roughly 30% without dramatically increasing overdiagnosis.11PubMed. Prostate Cancer Foundation Screening Guidelines for Black Men in the United States If you are in one of these higher-risk categories, the standard 55-and-up screening window may be too late to catch a cancer that started growing years earlier.
What Happens If Your PSA Is Elevated
An elevated PSA does not mean you immediately get a biopsy. In many cases, your doctor will first consider additional blood- or urine-based biomarker tests to sharpen the picture. Tests such as the Prostate Health Index, 4Kscore, SelectMDx, and others have been developed specifically for this situation. They maintain high sensitivity for catching clinically important cancers while filtering out many of the false alarms that PSA alone produces.12PubMed. Blood- and urine-based biomarkers for the detection of clinically significant prostate cancer: a contemporary review Validation data from 2015 through 2023 show that these secondary biomarkers could spare roughly 15 to 50% of men from unnecessary biopsies while still catching 90 to 95% of the cancers that would warrant treatment.13Prostate Cancer and Prostatic Diseases. Evaluation of blood and urine based biomarkers for detection of clinically-significant prostate cancer
If the biomarker results still look worrisome, the next step is usually a multiparametric MRI (mpMRI) of the prostate. This specialized scan produces detailed images of the gland and flags suspicious areas on a five-point scale called PI-RADS. Low scores (PI-RADS 1 or 2) suggest cancer is unlikely; a study of men with these negative MRI results found that about 91% did not have clinically significant cancer.14PubMed Central. Can a prostate biopsy be safely deferred on PI-RADS 1,2 or 3 lesions seen on pre-biopsy mp-MRI? Higher scores (PI-RADS 4 or 5) make a biopsy more likely. Intermediate scores (PI-RADS 3) land in a gray zone where biomarkers and clinical judgment help decide whether to biopsy or watch and repeat the MRI later.12PubMed. Blood- and urine-based biomarkers for the detection of clinically significant prostate cancer: a contemporary review Interestingly, research comparing full mpMRI to a simplified, faster version without contrast dye found no significant difference in cancer detection rates, which may eventually make the scans quicker and cheaper for patients.15PubMed. Prebiopsy Biparametric MRI for Clinically Significant Prostate Cancer Detection With PI-RADS Version 2: A Multicenter Study
When a Biopsy Is Needed
If the screening cascade points toward a real concern, a prostate biopsy is the only way to confirm whether cancer is present. There are two main routes to the prostate: through the rectum (transrectal) and through the perineum, the patch of skin between the scrotum and the anus (transperineal). The transperineal approach has gained ground in recent years because it avoids pushing a needle through the rectal wall, which greatly reduces the risk of serious infection. Because the needle does not travel through bacteria-rich rectal tissue, professional guidelines now say antibiotics can often be skipped entirely for transperineal biopsies.16PubMed Central. Developments in optimizing transperineal prostate biopsy
During the procedure, the doctor uses ultrasound (and often MRI data fused into the ultrasound image) to guide a thin needle into the prostate, taking multiple small tissue samples, typically 12 or more cores, from different regions of the gland.17PubMed Central. Transperineal prostate biopsy: a review of technique Transperineal biopsies have traditionally been done under general anesthesia, but newer freehand techniques can be performed with local anesthesia or sedation, making the procedure an outpatient experience for many men.16PubMed Central. Developments in optimizing transperineal prostate biopsy
After the Biopsy
Minor side effects after a prostate biopsy are common and usually resolve on their own. You can expect some blood in the urine, semen, or stool for a few days to a couple of weeks. Some soreness or bruising around the biopsy site is normal, and mild urinary symptoms like burning or frequency may linger briefly.18European Urology. Systematic Review of Complications of Prostate Biopsy Serious complications are less common but do occur, with infection being the most worrisome. If you develop a fever, chills, or difficulty urinating after a biopsy, you should contact your doctor right away. Guidelines recommend that clinicians assess each patient’s infection risk beforehand and use targeted antibiotic strategies when a transrectal approach is chosen.19PubMed. An Update of the American Urological Association White Paper on the Prevention and Treatment of the More Common Complications Related to Prostate Biopsy
Understanding Biopsy Results
If cancer is found, the pathologist assigns a Gleason grade group, a score that describes how aggressive the cancer cells look under a microscope. Lower scores (grade group 1, the old Gleason 6) suggest a slow-growing cancer, while higher numbers indicate more aggressive disease. The grade your biopsy reports is important but not always the final word. Because the biopsy needle samples only small slivers of the prostate, it can miss areas where the cancer is more aggressive. One large study found that about two-thirds of men diagnosed with the lowest-grade cancer on biopsy were upgraded to a higher grade once the whole prostate was examined after surgery.20BJU International. Underestimation of Gleason score at prostate biopsy reflects sampling error in lower volume tumours This upgrading was most common in smaller tumors, where the biopsy needle had less tissue to catch. It is one reason doctors do not rely on biopsy grade alone when making treatment decisions; MRI findings, PSA trends, and the number of positive cores all feed into the picture.
Overdiagnosis and Active Surveillance
One of the biggest criticisms of prostate screening is that it finds cancers that would never have caused harm. A substantial proportion of prostate cancers detected through screening are indolent, meaning they grow so slowly that a man is far more likely to die of something else entirely.21PubMed Central. Overdiagnosis and overtreatment of early detected prostate cancer Treating these cancers with surgery or radiation exposes men to serious side effects for minimal benefit, a pattern that has prompted a major shift in how low-risk prostate cancer is managed.
Active surveillance has emerged as the preferred strategy for men whose cancer appears low-risk. Rather than jumping to surgery or radiation, the man is monitored with regular PSA tests, periodic biopsies, and sometimes MRI. If follow-up testing shows the cancer is becoming more aggressive, treatment is offered at that point. The goal is to avoid treating cancers that do not need treating while preserving the opportunity to act if the situation changes.22PubMed. Active surveillance for prostate cancer: overview and update Contemporary data suggest that the use of active surveillance has increased worldwide, reflecting a growing consensus that for favorable-risk cancers, watchful monitoring is not neglect but a considered medical strategy.23Nature Reviews Urology. Active surveillance for prostate cancer: current evidence and contemporary state of practice
AI-Enhanced Imaging on the Horizon
The prostate exam of the near future may look quite different from today’s version. Researchers are developing AI-powered micro-ultrasound systems that combine risk assessment and biopsy guidance into a single device, potentially replacing some of the MRI step. In one study, an AI model trained on micro-ultrasound images achieved sensitivity of about 93% for clinically significant cancer while nearly tripling the specificity of the standard screening combination of PSA, DRE, age, and prostate volume.24PubMed Central. AI-enhanced micro-ultrasound improves detection of clinically significant prostate cancer at biopsy A separate team found that their deep-learning model actually detected more cancer lesions than experienced urologists reading the same images, with lesion-level sensitivity of 73% for the AI versus 58% for the human readers.25PubMed Central. ProMUS-NET: Artificial intelligence detects more prostate cancer than urologists on micro-ultrasonography These systems are still in early validation, but the idea of an in-office, real-time imaging tool that could reduce the need for expensive MRI scans and lower false-positive rates is genuinely promising. It will not replace the PSA blood draw or the conversation with your doctor, but it could make the steps that follow an abnormal screening result faster, less invasive, and more accurate.